Oncology (Solid Tumors)
Tests applicable to Individuals who fall in one or more of the categories mentioned below.
1. Members of families with a history of cancer.
2. Cancer patients who may benefit from pharmacotherapeutic guidance and stratification for prognosis.
3. Early onset breast cancer or triple negative breast cancer.
4. Early onset colon, ovarian, renal, lung cancer, etc.
5. Patients diagnosed with multiple primary cancers.
6. Patients with an identified hereditary cancer syndrome.
| Test No. | Test Name | Analytical Technique | Sample required | TAT |
| ONCNGS168 | BRAF V600 region sequencing | NGS | Paraffin block/ Fresh tissue | 4-5 weeks |
| ONCNGS160 | KRAS mutation analysis (codons 12, 13, 61 & 146) by NGS | NGS | Paraffin Block/ Fresh tissue | 4-5 weeks |
| ONCNGS158 | EGFR mutation analysis (exons 18, 19, 20 and 21) by NGS | NGS | Paraffin Block/ Fresh tissue | 4-5 weeks |
| ONCNGS387 | EGFR T790M Quantitative mutation detection by NGS | NGS | Paraffin Block/ Fresh tissue | 4-5 weeks |
| ONCNGS236 | EGFR (exons 18, 19, 20 and 21) and KRAS (codons 12, 13, 61 and 146) ultradeep mutation analysis by Next Generation Sequencing | NGS | Paraffin Block/ Fresh tissue | 4-5 weeks |
| ONCNGS045 | BRCause NGS Panel – Full sequencing of BRCA1 and BRCA2 | NGS | Blood in EDTA | 4-5 weeks |
| ONCNGS046 | BRCause Extended NGS Panel – Full sequencing of BRCA1, BRCA2, ATM, BRIP1, NBN, RAD51C, RAD51D, PALB2, STK11, CHEK2, PTEN, TP53, CDH1, MLH1, MSH2, MSH6, PMS2, APC, SMAD4, BLM, FANCC, ERCC2 and EPCAM genes | NGS | Blood in EDTA | 4-5 weeks |
| ONCMLP203 | BRCopy: BRCA1, BRCA2 copy number variations and large gene rearrangements | MLPA | Blood in EDTA | 10 days |
| ONCNGS393 | Germline panel for FAP (Familial Adenomatous Polyposis) (Next Generation Sequencing of APC, MUTYH genes) | NGS | Blood in EDTA | 4-5 weeks |
| ONCNGS241 | Germline Panel for Hereditary Non-polyposis Colorectal Carcinoma (HNPCC)/ Lynch Syndrome (Next Generation Sequencing of EPCAM, MLH1, MSH2, MSH6 and PMS2) | NGS | Blood in EDTA | 4-5 weeks |
| ONCNGS244 | Next Generation Sequencing panel for Multiple Endocrine Neoplasia (MEN) including RET and MEN1 genes | NGS | Blood in EDTA | 4-5 weeks |
| ONCNGS248 | Retinoblastoma (RB1 gene Next Generation Sequencing) | NGS | Blood in EDTA | 4-5 weeks |
| ONCFRG429 | Microsatellite Instability (MSI) by Fragment analysis | Fragment Analysis | FFPE Blocks/ Tissue + Blood in EDTA | 2 weeks |
| ONCMLP389 | MLPA for Von Hippel Lindau (VHL) Syndrome | MLPA | Blood in EDTA | 10 days |
| NEPSEQ272 | Von Hippel Lindau Syndrome (Sequencing of exons 1, 2 and 3 of the VHL gene) | CE-Seq | Blood in EDTA | 2-3 weeks |
| ONCSEQ399 | Targeted sequencing in VHL, gene (for family members at risk) | CE-Seq | Blood in EDTA | 2 weeks |
| INDHC2440 | Human Papillomavirus (HPV) testing for Cervical Cancer Risk by HC2 | Hybrid Capture 2 | Cervical specimen in SurePath collection vial | Every Thursday |
| INDNGS441 | Human Papillomavirus (HPV) genotyping by NGS (RUO) | NGS | Cervical specimen in SurePath collection vial | 4-5 weeks |